HUP0500025A2 - Tisztított lasofoxifene és eljárás racém lasofoxifene tisztítására átkristályosítással - Google Patents

Tisztított lasofoxifene és eljárás racém lasofoxifene tisztítására átkristályosítással

Info

Publication number
HUP0500025A2
HUP0500025A2 HU0500025A HUP0500025A HUP0500025A2 HU P0500025 A2 HUP0500025 A2 HU P0500025A2 HU 0500025 A HU0500025 A HU 0500025A HU P0500025 A HUP0500025 A HU P0500025A HU P0500025 A2 HUP0500025 A2 HU P0500025A2
Authority
HU
Hungary
Prior art keywords
lasofoxifene
purified
recrystallization
purification
racemic
Prior art date
Application number
HU0500025A
Other languages
English (en)
Inventor
Robert William Mclaughlin
Constantine Sklavounos
Harry Austin Watson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0500025A2 publication Critical patent/HUP0500025A2/hu
Publication of HUP0500025A3 publication Critical patent/HUP0500025A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgya eljárás szennyezőanyagok eltávolítására racém cisz-6-fenil-[4-(2-pirrolidin-l-iletoxi)fenil]-5,6,7,8-tetrahidronaftalin-2-olból, valamint a tisztított cisz-6-fenil-[4-(2-pirrolidin-l-iletoxi)fenil]5,6,7,8-tetrahidronaftalin-2-ol, amely ösztrogénagonistaként/antagonistaként alkalmazható. Ó
HU0500025A 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization HUP0500025A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36887202P 2002-03-28 2002-03-28
PCT/IB2003/001033 WO2003082814A1 (en) 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Publications (2)

Publication Number Publication Date
HUP0500025A2 true HUP0500025A2 (hu) 2005-04-28
HUP0500025A3 HUP0500025A3 (en) 2005-10-28

Family

ID=28675551

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500025A HUP0500025A3 (en) 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Country Status (23)

Country Link
US (2) US6906202B2 (hu)
EP (1) EP1487790B1 (hu)
JP (1) JP4268055B2 (hu)
KR (1) KR100636953B1 (hu)
CN (1) CN1283625C (hu)
AR (1) AR039152A1 (hu)
AT (1) ATE459599T1 (hu)
AU (1) AU2003209603B2 (hu)
BR (1) BR0308758A (hu)
CA (1) CA2479924C (hu)
DE (1) DE60331527D1 (hu)
DK (1) DK1487790T3 (hu)
ES (1) ES2339936T3 (hu)
HK (1) HK1073111A1 (hu)
HU (1) HUP0500025A3 (hu)
IL (2) IL162929A0 (hu)
MX (1) MXPA04009259A (hu)
PL (1) PL372727A1 (hu)
RS (1) RS80604A (hu)
RU (1) RU2278861C2 (hu)
TW (1) TW200306974A (hu)
WO (1) WO2003082814A1 (hu)
ZA (1) ZA200405209B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479924C (en) * 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CN102311406A (zh) * 2010-06-29 2012-01-11 武汉启瑞药业有限公司 拉索昔芬中间体的制备方法
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
KR102412089B1 (ko) 2021-09-13 2022-06-22 주식회사 세라수 Dmts의 정제방법
KR102663941B1 (ko) 2024-03-04 2024-05-08 주식회사 세라수 Drometrizole trisiloxane(DMTS)의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326865A (en) * 1990-06-08 1994-07-05 Hercules Incorporated Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
EP0756205A3 (en) * 1995-07-26 1998-10-14 Eastman Kodak Company Pattern transfer techniques for fabrication of lenslet arrays using specialized polyesters
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6180375B1 (en) 1999-08-27 2001-01-30 Pfizer Inc. Microbial biotransformation
HUP0401391A3 (en) 2001-05-01 2009-06-29 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency and the pharmaceutical compositin
CA2479924C (en) * 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Also Published As

Publication number Publication date
US20050171189A1 (en) 2005-08-04
PL372727A1 (en) 2005-07-25
AU2003209603A1 (en) 2003-10-13
KR20040108693A (ko) 2004-12-24
DK1487790T3 (da) 2010-05-10
JP2005521727A (ja) 2005-07-21
CA2479924C (en) 2008-07-15
KR100636953B1 (ko) 2006-10-19
EP1487790B1 (en) 2010-03-03
RU2004128931A (ru) 2005-04-10
US6906202B2 (en) 2005-06-14
CN1283625C (zh) 2006-11-08
EP1487790A1 (en) 2004-12-22
US7358374B2 (en) 2008-04-15
AR039152A1 (es) 2005-02-09
WO2003082814A1 (en) 2003-10-09
BR0308758A (pt) 2004-12-28
TW200306974A (en) 2003-12-01
AU2003209603B2 (en) 2008-07-17
MXPA04009259A (es) 2005-01-25
ZA200405209B (en) 2005-08-31
IL162929A0 (en) 2005-11-20
CA2479924A1 (en) 2003-10-09
RS80604A (en) 2007-02-05
ES2339936T3 (es) 2010-05-27
ATE459599T1 (de) 2010-03-15
HUP0500025A3 (en) 2005-10-28
CN1625548A (zh) 2005-06-08
US20030212122A1 (en) 2003-11-13
DE60331527D1 (de) 2010-04-15
IL162929A (en) 2009-11-18
HK1073111A1 (en) 2005-09-23
RU2278861C2 (ru) 2006-06-27
JP4268055B2 (ja) 2009-05-27

Similar Documents

Publication Publication Date Title
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
ITMI20022076A1 (it) Sali di intermedi del cefdinir.
HUP0500025A2 (hu) Tisztított lasofoxifene és eljárás racém lasofoxifene tisztítására átkristályosítással
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
AU2003258146A1 (en) Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
EA200300804A1 (ru) Усовершенствованный способ получения карбапенема
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
ATE425121T1 (de) Verfahren zur umwandlung von polysulfanen
RS52260B (en) N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
WO2003084942A3 (en) Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
NO20060922L (no) Ny fremgangsmate for syntesen av perindopril og dens farmasoytiske akseptable salter
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
GB0511682D0 (en) Process for the separation of racemic mixtures
HUP0400767A2 (hu) Javított eljárás tiszta ondansetron-hidroklorid-dihidrát előállítására
AU2003303563A1 (en) Process for synthesizing amine from nitrile
EP1553073A4 (en) PROCESS FOR PREPARING 1,2,4-BUTANTRIOL
ATE414704T1 (de) Verfahren zur synthese von pergolid
AU2003302339A1 (en) Process for synthesizing amine from nitrile
ATE500247T1 (de) Verfahren zur herstellung von 3-(1,3- dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als dopamin-beta-hydroxylase inhibitor
EP1489072A4 (en) METHOD FOR THE ASYMMETRIC INTRAMOLECULAR 3 + 2 CYCLOADDITION OF HYDRAZONES
TW200621749A (en) Process for preparing n-(substituted arylmethyl)-4-substituted-4-(disubstituted methyl)piperidines and intermediates
WO2003106425A3 (fr) Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf
MXPA05009153A (es) Proceso para preparar 2-metilpirrolidina y enantiomeros especificos de la misma.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees